Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
Guoqing Gu,1,* Chenxi Hu,1,* Kaiyuan Hui,1 Huiqin Zhang,1 Ting Chen,1 Xin Zhang,2 Xiaodong Jiang1 1Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, 222000, People’s Republic of China; 2Lianyungang Clinical College of Nanj...
Guardado en:
Autores principales: | Gu G, Hu C, Hui K, Zhang H, Chen T, Zhang X, Jiang X |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/40ea827694da4063ae886ee12768c438 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Mengqiu Tang, et al.
Publicado: (2021) -
Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021) -
Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Mei Luo, et al.
Publicado: (2021) -
Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
por: Yuying Gan, et al.
Publicado: (2021) -
A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
por: Yang H, et al.
Publicado: (2021)